Altre lingue Annexon, Inc.

Azioni

ANNX

US03589W1027

Biotecnologia

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 16/01/2025			Variaz. 5gg	Var. 1 gen.
4,110 ^USD	-3,07%		-15,08%	-19,88%

15/01	Annexon, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 03:00 PM
10/01	Annexon, Inc. nomina William ?BJ? Jones nel suo Consiglio di Amministrazione	CI

Altre lingue

Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones	13/01
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year	13/01
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year	13/01
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones	10/01
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones	10/01
Annexon, Inc. Appoints William ?BJ? Jones to Its Board of Directors	10/01
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference	07/01
Annexon, Inc.(NasdaqGS:ANNX) added to NASDAQ Biotechnology Index	23/12
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4)	17/12
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin or Plasma Exchange in a Matched Patient Cohort for the Treatment of Guillain-Barre Syndrome	17/12
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	16/12
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	16/12
Annexon : Announces Positive Topline Results from Real World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain Barré Syndrome (GBS) Form 8 K	16/12
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)	16/12
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome	16/12
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting	05/12
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4)	18/11
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	15/11
Annexon : Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Form 8 K	14/11
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones	14/11
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones	14/11
Annexon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	14/11
Annexon Biosciences to Present at the Jefferies London Healthcare Conference	13/11
Annexon : Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting Form 8 K	22/10/24
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting	22/10/24

Iscriviti per accedere a più notizie

Registrazione 100% gratuita

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Annexon, Inc.

Azioni

ANNX

US03589W1027

Biotecnologia

Altre lingue

Filtri